A Pilot Study of Etanercept Treatment for Pemphigus Vulgaris
Open Access
- 20 September 2010
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Dermatology
- Vol. 147 (1) , 117-118
- https://doi.org/10.1001/archdermatol.2010.409
Abstract
Pemphigus vulgaris (PV) is a chronic autoimmune blistering disease associated with a high morbidity rate and potential mortality. Current therapies are not uniformly effective and are associated with potential adverse effects; thus, there is a need for new therapeutic options for PV.Keywords
This publication has 3 references indexed in Scilit:
- Reliability and Convergent Validity of Two Outcome Instruments for PemphigusJournal of Investigative Dermatology, 2009
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigusPublished by Elsevier ,2008
- Successful Treatment of Recalcitrant Pemphigus Vulgaris and Pemphigus Vegetans With Etanercept and Carbon Dioxide LaserArchives of Dermatology, 2005